Document Detail


Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis.
MedLine Citation:
PMID:  2213378     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ten children with renal failure (age range 2 years 6 months to 18 years 9 months; median 11 years 10 months), maintained by long-term hemodialysis, had successful correction of their anemia after intravenous administration of recombinant human erythropoietin in a dosage escalating every 2 weeks (75 to 150 to 300 to 450 IU/kg/wk). Mean hemoglobin concentration increased from 6.4 +/- 0.9 to 11.5 +/- 1.0 gm/dl. Blood cell counts used to evaluate the correction of anemia were done after dialysis; this was especially important for children less compliant with water restriction. The higher hemoglobin concentration resulted in improvement of the quality of life, a greater tolerance for physical effort (exercise tolerance doubled and the ventilatory anaerobic threshold increased significantly), correction of some subclinical central nervous system abnormalities detected by evoked potentials testing, and reduction of bleeding time. Few side effects were noted; severe hypertension developed in one patient when postdialysis hematocrit was only 28%, and there were two episodes of hypertransaminasemia with no other evidence of liver dysfunction. We conclude that in children with renal failure the use of recombinant human erythropoietin to correct anemia is safe and strongly advisable, because of the resolution of many of the symptoms correlated with anemia.
Authors:
G Montini; G Zacchello; E Baraldi; S Zanconato; A Suppiej; F Fabris; B Andreetta; L Pavanello; F Zacchello
Related Documents :
11533918 - Hemodialysis in the pediatric patient: state of the art.
21318018 - The impact of nutritional status and longitudinal recovery of motor and cognitive miles...
3153348 - Childhood renal diseases in korea. a clinicopathological study of 657 cases.
16221088 - Renal tubular function in children with beta-thalassemia minor.
10937458 - Common brain tumours in children: diagnosis and treatment.
11181858 - Depth of lesion model in children and adolescents with moderate to severe traumatic bra...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of pediatrics     Volume:  117     ISSN:  0022-3476     ISO Abbreviation:  J. Pediatr.     Publication Date:  1990 Oct 
Date Detail:
Created Date:  1990-11-05     Completed Date:  1990-11-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0375410     Medline TA:  J Pediatr     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  556-60     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatrics, University of Padua, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anemia, Hemolytic / etiology,  therapy*
Blood Coagulation Tests
Child
Child, Preschool
Erythropoietin / therapeutic use*
Evoked Potentials, Auditory, Brain Stem
Evoked Potentials, Somatosensory
Heart Function Tests
Hematocrit
Humans
Recombinant Proteins / therapeutic use
Renal Dialysis / adverse effects*
Respiratory Function Tests
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diagnosis of cerebrovascular disease in sickle cell anemia by magnetic resonance angiography.
Next Document:  Patterns of food hypersensitivity during sixteen years of double-blind, placebo-controlled food chal...